A marketing authorisation is not a permanent asset by default. It must be renewed once, after five years, and it can lapse in practice if the product is never launched or disappears from the market. Missing either obligation can end an authorisation that took years to obtain.
The five-year renewal
Under Article 24 of Directive 2001/83/EC, an authorisation is initially valid for five years. To renew it, the marketing authorisation holder (MAH) must submit a consolidated file on quality, safety and efficacy, which the authority uses to re-evaluate the benefit-risk balance. The application is due at least nine months before the authorisation would otherwise expire. The same nine-month rule appears in the EMA guideline for centrally authorised products.
A renewal is a benefit-risk re-evaluation, not a new assessment of the whole dossier. In the centralised procedure, the EMA guideline expects, among other elements:
- an addendum to the clinical overview that critically discusses the current benefit-risk balance;
- a discussion of submitted PSURs, adverse reaction reports, pharmacovigilance activities and the effectiveness of risk minimisation;
- an addendum to the quality overall summary, together with a GMP certificate and Qualified Person declarations.
Once renewed, the authorisation is normally valid for an unlimited period. The authority may, on justified pharmacovigilance grounds, require one further five-year renewal, for example where too few patients have been exposed to the product.
The sunset clause
Article 24 also provides that an authorisation lapses if the product is not actually placed on the market in the authorising Member State within three years of the grant. It lapses likewise if a product that was marketed is no longer actually available there for three consecutive years. Authorities may grant an exemption in exceptional circumstances and on public health grounds, but any exemption must be duly justified. It cannot be assumed.
Where companies get caught out
- Calendar drift. The nine-month deadline is counted back from expiry, so internal planning must start well before it.
- Gaps in the file. A renewal depends on a coherent pharmacovigilance and variation history. Missing PSURs or unresolved commitments surface at this stage.
- Dormant products. Authorisations held for portfolio reasons, or products withdrawn because of supply or pricing difficulties, can approach the three-year threshold unnoticed.
- Group-wide assumptions. The clause is applied by Member State, so a product that is active elsewhere in the EU can still be at risk in Greece.
EU pharmaceutical legislation is being reformed, so the legal basis and any national guidance in force should be confirmed before any decision is taken.
How PQRA helps
PQRA maintains regulatory calendars for authorisation portfolios in Greece and the EU, prepares renewal dossiers and consolidated files, aligns the pharmacovigilance record behind them, and advises on sunset-clause exposure and on exemption requests to the competent authority. We also help companies decide whether a dormant product should be relaunched, maintained or withdrawn in an orderly way.
Contact PQRA to review the renewal and sunset-clause position of your portfolio.


No responses yet